Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Bispecific Gamma Delta-T-Cell Engager Directed to EGFR

Geo Regions

Bispecific Gamma Delta-T-Cell Engager Directed to EGFR

PF-08046052 | SGN-EGFRd2 is an investigational compound. Its safety and efficacy have not been established.

Share to an HCP

Overview + Rationale

  • EGFR is a cell surface receptor expressed in many cancer types1
  • γ9δ2-T cells are a conserved T cell subset that can induce cell death in a wide range of malignancies2
  • Activated γ9δ2-T cells directly induce cell lysis as well as activate downstream innate and adaptive immune cells, enhancing tumor cell killing3-5
  • PF-08046052 (SGN-EGFRd2) is a novel, investigational bispecific gamma delta (γδ)-T cell engager directed to EGFR, comprising a bispecific humanized heavy chain-only antibody designed to conditionally activate γ9δ2-T cells by simultaneously binding EGFR and γ9δ2 TCR6
  • Full activation of γ9δ2-T cells and tumor-directed cytotoxicity requires the presence of pAg, a stress signal found in malignant cells, but not in healthy cells6,7

Mechanism of Action

Stage of Development

Other
Advanced Solid Tumors*
Phase 1 Monotherapy
This information is current as of April 29th 2025.

*Colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, pancreatic ductal adenocarcinoma

EGFR, epidermal growth factor receptor.  

REFERENCES:  1. Thomas R. Front Oncol. 2019: 800. 2. Melandri D. Nat Immunol. 2018: 1352-65. 3. Devilder MC. J Immunol. 2006: 1386-96. 4. Vantourout P. Nat Rev Immunol. 2013: 88-100. 5. Brandes M. Science. 2005: 264-8. 6. King LA. Cancer Immunol Res. 2023: 1237-52. 7. Yuan L. Nature. 2023: 840-8. 8. Clinicaltrials.gov. NCT05983133. Available at: https://clinicaltrials.gov/study/NCT05983133. Accessed April 13, 2025.